Audevard announces the acquisition of imaverol® and invests in the development of the equine therapeutic armoury
Audevard announced today the acquisition of Imaverol®, a brand owned until now by Elanco Animal Health. The perimeter also includes the entire equine R&D projects including Vulketan®.
This acquisition reinforces the pledge Audevard has taken to become the partner of the equine veterinarian accross Europe. This ambition was first evoked in 2015 when the firm was taken over by its management and investment funds. Since this time, Audevard bought Tildren®, Europe’s first bisphosphonate, and has continued to grow rapidly accross Europe as much in their pharmaceutical range as in their nutraceutical range.
With this new brand, Audevard has made substantial progress towards its growth by incorporating pharmaceutical drugs that help veterinarians protect equine health on a daily basis.
Indeed Imaverol®, made with enilconazole, has been valued by practitionners for its antifungal properties for over 30 years and appreciated all over Europe for its versatility.
The range of R&D projects acquired includes Vulketan®, a unique solution adapted to the horse’s specific wound healing process. Audevard having positionned itself as the defender of the equine therapeutic armoury will invest in maintaining this brand that will be relaunched in time. The other R&D projects are orientated towards new therapeutic goals providing equine vets with innovating pharmaceutical solutions.
Marina Wissink, President of Audevard, spoke on the agreement ‘The equine market is extremely fragmented. Because pharmaceutical companies lack critical mass, the support that can be directed towards the veterinary sector is limited. This acquisition is a major step for Audevard because it strengthens our ties with all equine veterinarians accross Europe. We are pursuing an ambitious strategy of organic and external growth because growth is the only factor that will allow us to invest further in the development of medical and non-medical equine services and products’